FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

被引：0
|
作者：
Moore, K. [1 ]
Oza, A. [2 ]
Colombo, N. [3 ,4 ]
Oaknin, A. [5 ]
Scambia, G. [6 ]
Lorusso, D. [7 ]
Farias-Eisner, R. [8 ]
Banerjee, S. [9 ]
Murphy, C. [10 ]
Tanyi, J. [11 ]
Hirte, H. [12 ]
Konner, J. [13 ]
Lim, P. [14 ]
Hayes, M. Prasad [15 ]
Monk, B. [16 ]
Kim, S. [17 ]
Wang, J. [18 ]
Pautier, P. [19 ]
Vergote, I. [20 ]
Birrer, M. [21 ]
机构：
[1] Univ Oklahoma, Dept Obstet & Gynecol Univ, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[3] European Inst Oncol, Dept Gynecol Oncol, Milan, Italy
[4] Univ Milano Bicocca, Milan, Italy
[5] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[6] Univ Cattolica, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Gynecol Oncol, Milan, Italy
[8] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA
[9] Royal Marsden Hosp NHS Fdn Trust, Gynaecol, London, England
[10] Bon Secours Hosp, Med Oncol, Cork, Ireland
[11] Univ Penn, Obstet & Gynecol, Philadelphia, PA 19104 USA
[12] Juravinski Canc Ctr, Oncol, Hamilton, ON, Canada
[13] Mem Sloan Kettering Canc Ctr, Gynecol Oncol, 1275 York Ave, New York, NY 10021 USA
[14] Ctr Hope, Gynecol Oncol, Reno, NV USA
[15] Icahn Sch Med Mt Sinai, Obstet & Gynecol, New York, NY 10029 USA
[16] Creighton Univ, Univ Arizona, St Josephs Hosp, Gynecol Oncol,Arizona Oncol,Coll Med,Sch Med, Phoenix, AZ USA
[17] Univ Texas Houston, McGovern Med Sch, Houston, TX USA
[18] ImmunoGen Inc, Clin Dev, Waltham, MA USA
[19] Gustave Roussy, Med, Villejuif, France
[20] Univ Hosp Leuven Campus Gasthuisberg, Gynaecol, Leuven, Belgium
[21] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, MA USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
992O
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRa-positive, platinum-resistant ovarian cancer
    Konecny, Gottfried
    Moore, Kathleen
    Lebreton, Coriolan
    Weroha, Saravut
    Romeo Marin, Margarita
    McAvan, Lucy
    Colombo, Nicoletta
    O'Malley, David
    Coffman, Lan
    Roszak, Andrzej
    Shapira-Frommer, Ronnie
    Lalisang, Roy
    Cibula, David
    Barquin, Arantzazu
    Glasspool, Rosalind
    Stec, James
    Li, Lingling
    Method, Michael
    Hardy-Bessard, Anne Claire
    Van Gorp, Toon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S11 - S12
  • [42] A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC)
    Burris, Howard A.
    Gordon, Michael S.
    Gerber, David E.
    Spigel, David R.
    Mendelson, David S.
    Schiller, Joan H.
    Wang, Yulei
    Choi, Younleong
    Kahn, Robert S.
    Wood, Katie
    Maslyar, Daniel J.
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study
    Coleman, Robert
    Oaknin, Ana
    Pignata, Sandro
    Denys, Hannelore
    Colombo, Nicoletta
    Van Gorp, Toon
    Konner, Jason
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth
    Esteves, Brooke
    Method, Michael
    Lorusso, Domenica
    Matulonis, Ursula
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S3 - S3
  • [44] PHARMACOKINETICS OF ANTIBODY-DRUG CONJUGATE (ADC)-DNIB0600A IN A PHASE I STUDY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (OC)/NON-SMALL CELL LUNG CANCER (NSCLC).
    Xu, J.
    Burris, H., III
    Gordon, M.
    Gerber, D.
    Choi, Y.
    Lin, K.
    Maslyar, D.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S32 - S32
  • [45] MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib plus dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).
    Randall, Leslie M.
    O'Malley, David M.
    Monk, Bradley J.
    Coleman, Robert L.
    Gaillard, Stephanie
    Adams, Sarah F.
    Duska, Linda R.
    Cappuccini, Fabio
    Dalton, Heather
    Holloway, Robert W.
    Huang, Marilyn
    Chon, Hye Sook
    Cloven, Noelle Gillette
    ElNaggar, Adam
    O'Cearbhaill, Roisin Eilish
    Waggoner, Steven E.
    Wang, Zebin
    Zhi, Eric
    Samnotra, Vivek
    Konstantinopoulos, Panagiotis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] PHARMACOKINETICS (PK) OF ANTI-MSLN ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH UNRESECTABLE PANCREATIC OR PLATINUM-RESISTANT OVARIAN CANCER IN A PHASE I STUDY.
    Samineni, D.
    Li, C.
    Nazzal, D.
    Maslyar, D.
    Li, D.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S46 - S46
  • [47] Efficacy and safety of mirvetuximab soravtansine in Chinese patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from IMGN853-301 (Soraya China) study
    Li, Li
    Wu, Yong
    Li, Qingshui
    Yu, Aijun
    Lin, An
    Li, Guiling
    Zhang, Huifeng
    Wang, Jing
    Li, Li
    Yin, Rutie
    Wei, Bing
    Li, Jundong
    Chen, Lihong
    Zhao, Weidong
    Wang, Wuliang
    Zhang, Qinghua
    Xu, June
    Wu, Xiaohua
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A210 - A210
  • [48] A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)
    Weekes, Colin D.
    Lamberts, Laetitia E.
    Borad, Mitesh J.
    Voortman, Johannes
    McWilliams, Robert R.
    Diamond, Jennifer Robinson
    De Vries, Elisabeth
    Verheul, Henk M. W.
    Lieu, Christopher Hanyoung
    Yue, Huibin
    Wang, Yulei
    Scales, Suzie
    Samineni, Divya
    Wood, Katie
    Brunstein, Flavia
    Maslyar, Daniel J.
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] PHARMACOKINETICS OF A THIOMAB™ ANTIBODY DRUG CONJUGATE: DMUC4064A IN A PHASE I STUDY OF PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER.
    Wang, B.
    Kagedal, M.
    Leipold, D.
    Saad, O.
    Garg, A.
    Girish, S.
    Humke, E.
    Moore, K.
    Hamilton, E.
    Howard, B.
    Wang, J.
    Birrer, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S75 - S75
  • [50] PHASE 1 DOSE-ESCALATION STUDY OF STRO-002, AN ANTI-FOLATE RECEPTOR ALPHA (FRα) ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED PLATINUM-RESISTANT/REFRACTORY EPITHELIAL OVARIAN CANCER (OC)
    Naumann, R.
    Braiteh, F.
    Diaz, J.
    Hamilton, E.
    Diab, S.
    Schilder, R.
    Moroney, J.
    Martin, L.
    Uyar, D.
    O'Malley, D.
    Penson, R.
    DiLea, C.
    Palumbo, M.
    DeAlmeida, V.
    Berman, C.
    Matheny, S.
    Molina, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A61 - A61
12345